• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

FDA Approves Eli Lilly’s Zepbound for Chronic Weight Management

cafead

Administrator
Staff member
  • cafead   Nov 08, 2023 at 10:12: PM
via Eli Lilly announced Wednesday that the FDA has approved its Zepbound (tirzepatide) injection for chronic weight management in adults with obesity or excessive weight with at least one weight-related condition, such as hypertension, type 2 diabetes or high cholesterol.

article source
 

<